Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-3167.63%
operating margin TTM
-2963.0%
revenue TTM
15.29 Million
revenue per share TTM
0.1$
valuation ratios | |
|---|---|
| pe ratio | -7.45 |
| peg ratio | -0.07 |
| price to book ratio | 6.82 |
| price to sales ratio | 235.78 |
| enterprise value multiple | -9.07 |
| price fair value | 6.82 |
profitability ratios | |
|---|---|
| gross profit margin | 22.0% |
| operating profit margin | -2963.0% |
| pretax profit margin | -3167.63% |
| net profit margin | -3167.63% |
| return on assets | -79.11% |
| return on equity | -80.0% |
| return on capital employed | -84.16% |
liquidity ratios | |
|---|---|
| current ratio | 8.13 |
| quick ratio | 8.13 |
| cash ratio | 7.43 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 874.31 |
| days of payables outstanding | 603.80 |
| cash conversion cycle | 270.52 |
| receivables turnover | 0.42 |
| payables turnover | 0.60 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | -49.73 |
| cash flow to debt ratio | -54.78 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.21 |
| cash per share | 0.35 |
| operating cash flow per share | -0.21 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -54.78 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -1,678.23 |
Frequently Asked Questions
When was the last time Mereo BioPharma Group plc (NASDAQ:MREO) reported earnings?
Mereo BioPharma Group plc (MREO) published its most recent earnings results on 10-11-2025.
What is Mereo BioPharma Group plc's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Mereo BioPharma Group plc (NASDAQ:MREO)'s trailing twelve months ROE is -80.0%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Mereo BioPharma Group plc (MREO) currently has a ROA of -79.11%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did MREO's net profit margin stand at?
MREO reported a profit margin of -3167.63% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is MREO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 8.13 in the most recent quarter. The quick ratio stood at 8.13, with a Debt/Eq ratio of 0.01.